BeOne Medicines (ONC) Long-Term Debt Repayments (2018 - 2026)

BeOne Medicines (ONC) has 6 years of Long-Term Debt Repayments data on file, last reported at $7.6 million in Q1 2026.

• On a quarterly basis, Long-Term Debt Repayments rose 81.28% year-over-year to $7.6 million in Q1 2026; TTM through Mar 2026 was $39.1 million, a 36.41% increase from a year earlier, with the FY2025 full-year figure at $35.7 million, up 27.29% from the prior year.
• Long-Term Debt Repayments for Q1 2026 stood at $7.6 million, down from $14.6 million in the prior quarter.
• Over the last five years, Long-Term Debt Repayments for ONC reached as high as $14.6 million in Q4 2025 and fell as low as $1.5 million in Q1 2023.
• Historically, Long-Term Debt Repayments has averaged $6.9 million across 4 years, with a median of $5.2 million in 2023.
• On a YoY basis, Long-Term Debt Repayments climbed as much as 199.77% in 2024 and fell as far as 57.92% in 2024.
• Year by year, Long-Term Debt Repayments stood at $5.2 million in 2023, then soared by 99.89% to $10.4 million in 2024, then soared by 39.89% to $14.6 million in 2025, then plunged by 47.73% to $7.6 million in 2026.
• Per Business Quant data, the three most recent Long-Term Debt Repayments figures were $7.6 million in Q1 2026, $14.6 million in Q4 2025, and $4.3 million in Q3 2025.